Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics


Zynerba Pharmaceuticals, Inc. (ZYNE): $4.56

-0.02 (-0.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZYNE Stock Summary

  • Zynerba Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.07% of US listed stocks.
  • With a price/sales ratio of 1,661.62, Zynerba Pharmaceuticals Inc has a higher such ratio than 99.79% of stocks in our set.
  • The volatility of Zynerba Pharmaceuticals Inc's share price is greater than that of 93.47% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Zynerba Pharmaceuticals Inc, a group of peers worth examining would be BPMX, RVNC, ADVM, PSTI, and PRTA.
  • Visit ZYNE's SEC page to see the company's official filings. To visit the company's web site, go to www.zynerba.com.

ZYNE Stock Price Chart Interactive Chart >

Price chart for ZYNE

ZYNE Price/Volume Stats

Current price $4.56 52-week high $9.00
Prev. close $4.58 52-week low $3.15
Day low $4.46 Volume 421,232
Day high $4.62 Avg. volume 2,898,470
50-day MA $4.35 Dividend yield N/A
200-day MA $4.53 Market Cap 188.11M

Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio


Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.


ZYNE Latest News Stream


Event/Time News Detail
Loading, please wait...

ZYNE Latest Social Stream


Loading social stream, please wait...

View Full ZYNE Social Stream

Latest ZYNE News From Around the Web

Below are the latest news stories about Zynerba Pharmaceuticals Inc that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.

Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 11:20 a.m. ET.

Intrado Digital Media | September 20, 2021

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome - Zynerba

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 (GLOBE NEWSWIRE) Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announces the initiation of []

Zynerba Pharmaceuticals | September 13, 2021

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome

Intrado Digital Media | September 13, 2021

Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with autism spectrum disorder (ASD) over a longer-term, 38-week treatment period . Zygel is cannabidiol formulated in a transdermal gel. The data were presented at The Full story available on Benzinga.com

Benzinga | September 9, 2021

Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

DEVON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today presented data from the Phase 2 BRIGHT trial describing tolerability and efficacy of Zygel (cannabidiol formulated in a transdermal gel [ZYN002]) in children and adolescents with autism spectrum disorder (ASD) over a longer term, 38-week treatment period. These data were presented as an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 being held virtually from September 9-10, 2021. A copy of the presentation is available on the Zynerba corporate website at http://zynerba.com/publications/ .

Intrado Digital Media | September 9, 2021

Read More 'ZYNE' Stories Here

ZYNE Price Returns

1-mo 9.88%
3-mo -13.80%
6-mo -4.60%
1-year 33.33%
3-year -44.12%
5-year -64.51%
YTD 38.18%
2020 -45.36%
2019 103.37%
2018 -76.28%
2017 -19.69%
2016 54.82%

Continue Researching ZYNE

Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:

Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.8027 seconds.